BICO operates in areas that are likely to witness strong demand growth over the long term, but technological innovation makes it difficult to pick the winners. BICO has struggled over the past year ...
Hosted on MSN
BICO sees 12% EBITDA margin improvement in Q4 2024, outlines strategic focus on lab automation and recurring revenues
Earnings Call Insights: BICO Group AB (OTCPK:CLLKF) Q4 2024 CEO Maria Forss highlighted that Q4 2024 revenue remained steady year-over-year at SEK571 million, with a 12 percentage point improvement in ...
BICO Group (OM:BICO) remains in the red, with net losses increasing at an annual rate of 43% over the past five years and a persistently negative profit margin. While the company is projected to stay ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
In this segment of "Industry Focus" on Motley Fool Live, recorded on Dec. 15, Fool Tech Host Dylan Lewis and Analyst Yasser El-Shimy discuss BICO Group's (BICO +2.41%) flagship product, the 3D ...
The Swedish company that commercialized the first bio-based ink in 2016 has moved far beyond bioprinting and on-demand biofabrication of human organs and tissues—especially after completing six ...
BICO Group AB reported its third-quarter 2025 earnings with notable revenue growth, leading to a significant stock price increase. The company’s net sales reached SEK 387 million, surpassing forecasts ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results